Global Tinea Pedis Treatment Market 2017-2021
About Tinea Pedis Treatment
Tinea pedis, also known as athlete’s foot, is caused by dermatophyte fungus on foot and can spread to toenails and hands. It is a dermatophyte infection of the soles of the feet and the interdigital spaces. Tinea pedis thrives in warm, humid conditions and is most common among young adult men. Tinea pedis can be transmitted through direct contact with an infected person or by touching surfaces contaminated with the fungus. This fungus lives in warm, moist environments and is found in showers, locker room floors, and swimming pools.
Technavio’s analysts forecast the global tinea pedis treatment market to grow at a CAGR of 3.03% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global tinea pedis treatment market for 2017-2021. To calculate the market size, the report considers the sales of both branded and generic drugs sales.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Tinea Pedis Treatment Market 2017-2021
Technavio recognizes the following companies as the key players in the global tinea pedis treatment market: GSK, Exeltis USA, Valeant, and Viamet Pharmaceuticals.
Other Prominent Vendors in the market are: Allergan, Almirall, Amgen, Aqua Pharmaceuticals, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dermira, Elorac, F. Hoffmann-La Roche, Galderma, Genentech, Hexima, Hisamitsu Pharmaceutical, Incyte, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharmaceuticals, Moberg Pharma, Mylan Pharmaceuticals, NanoBio , NovaBiotics, Novan , Nuvo Research, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Sun Pharma, Taro, Teva Pharmaceutical, Theravance Biopharma, and Tinea Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is increased funding for antifungal research. The growing cases of infectious diseases such as bacterial infection, fungal infection, and viral infection are encouraging vendors to enhance their R&D efforts in this therapy area. As drug development is a cost-intensive process, funding has always been a concern to vendors. This has led to various government and non-governmental institutes to take part in the development of antifungal drugs by providing the required funding to research institutes and companies.”
According to the report, one of the major drivers for this market is high unmet needs. The global tinea pedis treatment market faces significant unmet needs due to low treatment efficacy and prolonged treatment duration. Certain drugs show their efficacy only in the treatment of mild cases of infection. Also, the infection continues to recur as the treatment does not completely cure it. Multiple cycles of unsuccessful treatments increase patient discomfort. This creates a large gap between the demand for and supply of these therapeutics. Thus, the market provides a growth opportunity for vendors with the increasing demand for effective pharmacological therapeutics for fungal infections.
Further, the report states that one of the major factors hindering the growth of this market is increased availability of generics and alternative therapies. The easy availability of alternative treatments for tinea pedis can hamper the market growth. Alternative medications such as tea tree oil, Himalayan crystal salt, apple cider vinegar, garlic, neem oil, oregano oil are used to treat tinea pedis. Also, the preference for alternative therapies such as homeopathy and laser treatments restricts the market growth. Such instances also decrease the therapeutic share of the tinea pedis treatment market. Apart from this, the availability of generic products such as itraconazole, terbinafine, and fluconazole and the patent expiry of many drugs has led to a further decline in market shares.
GSK, Exeltis USA, Valeant, Viamet Pharmaceuticals, Allergan, Almirall, Amgen, Aqua Pharmaceuticals, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dermira, Elorac, F. Hoffmann-La Roche, Galderma, Genentech, Hexima, Hisamitsu Pharmaceutical, Incyte, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharmaceuticals, Moberg Pharma, Mylan Pharmaceuticals, NanoBio , NovaBiotics, Novan , Nuvo Research, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Sun Pharma, Taro, Teva Pharmaceutical, Theravance Biopharma, and Tinea Pharmaceuticals.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook